Bordeaux, Boston, April 21st, 2020 – 5:45pm CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee-surgery implants, today announced its revenue for the first quarter of 2020.
Before the impact of Covid-19, Implanet had a brisk start to the year and posted revenue of €1.51 million for the period ended March 16th, up from €1.31 million over the same period in 2019, representing double-digit growth of 15%.
*Unaudited data
Implanet CEO Ludovic Lastennet said: : “In keeping with the last quarters of 2019, 2020 kicked off well for Implanet. January and February were marked by strong sales momentum. We posted 15% growth before the impact of Covid-19 in March and even outperformed our forecasts for the Knee business. Unfortunately, the Covid-19 pandemic has resulted in the global suspension of non-urgent surgeries. When we take into account the extension of lockdown measures until at least mid-May, the impact on our business will continue into the second quarter. Our staff are poised to resume business as soon as possible, in order to retrieve the strong momentum we built at the start of the year.”
Upcoming financial events: – 2020 H1 revenue, July 7th, 2020 after market close – 2020 H1 results, 15th September, 2020 after market close |
A propos d’Implanet |
| Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around two product ranges, the latest generation JAZZ® implant, designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery, and the MADISON implant designed for first-line prosthetic knee surgery. Implanet’s tried-and-tested orthopedic platform is based on product traceability. Protected by four families of international patents, JAZZ® and MADISON have obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark as well as the ANVISA authorization in Brazil. Implanet employs 36 staff and recorded 2019 sales of €7.4 million. For further information, please visit www.Implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80 |
| www.implanet.com |
| To access the document in pdf please CLICK HERE |
| NEWCAP Sandrine Boussard-Gallien Investor relations Phone nb.: 01 44 71 20 40 Email: implanet@newcap.eu IMPLANET Ludovic Lastennet CEO Phone nb.: 05 57 99 55 55 Email: investors@implanet.com NEWCAP Nicolas Merigeau Media Relations Phone nb.: 01 44 71 94 98 Email: nmerigeau@newcap.fr |
